Als Akromegalie wird die klinische Manifestation eines bestehenden GH-Überschusses und des dadurch resultierenden erhöhten IGF-1-Spiegels bezeichnet. Die weit häufigste Ursache ist das Hypophysenadenom. Zur Diagnosestellung muss dem klinischen Verdacht die biochemische Krankheitsbestätigung folgen. Therapeutische Maßnahme der ersten Wahl ist die Operation, der zweiten die Medikation und der dritten die Bestrahlung. Die Therapie zielt auf die biochemische Remission (GH und IGF-1 normal), aber diese kann nicht immer erreicht werden. Abgesehen vom Fall einer nicht kontrollierten Akromegalie (pathologische GH- und IGF-1-Werte) kann auch eine biochemische Diskrepanz vorkommen. Präoperativer biochemischer Status, Tumorgröße, Tumorinvasivität und Wirkung der prä- oder postoperativen Medikation sowie die Radiotherapie können das Outcome beeinflussen. Ziel der vorliegenden Arbeit war die umfangreiche retrospektive Datenauswertung von Akromegaliepatienten. Auf der Basis des biochemischen Outcomes, welches auf die Effektivität der Therapie hinweist, wurden demographische, tumorassoziierte, medikamentenbedingte und operationsbezogene Daten detailliert analysiert.

Die Akromegalie - Folge eines Wachstumshormon (STH) sezernierenden Hypophysentumors - ist eine seltene Erkrankung. Bei früher Diagnose ist die Akromegalie gut behandelbar. Unbehandelt - oder zu spät behandelt - führt sie zu hoher Co-Morbidität und verkürzt das Leben. Endokrinologische Therapieziele wurden kürzlich definiert: Heilung bei STH / Acromegaly, caused by a growth hormone (GH)-secreting pituitary adenoma, is a rare disease. If diagnosed early therapeutic results are good. However, untreated or treated belatedly, acromegaly is associated with a high co-morbidity and reduced life-expectancy. The therapeutic goals have recently been defined as follows: complete remission or cure as GH

No description available.

(EN) GH/IGF-1 axis components (GH, growth hormone receptor (GH-R), IGF-1, IGF-1 receptor (IGF-1R), IGF-binding proteins (IGFBPs)) participate in the control of glucose metabolism, inflammatory processes as well as cell proliferation and differentiation, including adipocytes and monocytes. The aim of the present study was to evaluate the role of local mRNA expression of GH/IGF-1 axis components in subcutaneous adipose tissue (SCAT) and peripheral monocytes (PM) in the development of insulin resistance and differences of adipose tissue mass in following groups of patients: obese females with and without type 2 diabetes mellitus and subjects with active untreated acromegaly. A total number of 66 subjects were included in the study: obese females without type 2 diabetes mellitus (OB), obese females with type 2 diabetes mellitus (T2DM), acromegalic patients (AC) and healthy lean control subjects (C). T2DM underwent 2 weeks of very-low- calorie diet (VLCD - energy content 2500 kJ/day). According to our results we suggest that decreased mRNA expression of IGF-1, IGF-1R, IGFBP-2 and IGFBP-3 in adipose tissue of T2DM subjects may contribute to changes of fat differentiation capacity and the increased IGF-1R mRNA expression in peripheral monocytes in these patients may play a role in the regulation of...

(EN) GH/IGF-1 axis components (GH, growth hormone receptor (GH-R), IGF-1, IGF-1 receptor (IGF-1R), IGF-binding proteins (IGFBPs)) participate in the control of glucose metabolism, inflammatory processes as well as cell proliferation and differentiation, including adipocytes and monocytes. The aim of the present study was to evaluate the role of local mRNA expression of GH/IGF-1 axis components in subcutaneous adipose tissue (SCAT) and peripheral monocytes (PM) in the development of insulin resistance and differences of adipose tissue mass in following groups of patients: obese females with and without type 2 diabetes mellitus and subjects with active untreated acromegaly. A total number of 66 subjects were included in the study: obese females without type 2 diabetes mellitus (OB), obese females with type 2 diabetes mellitus (T2DM), acromegalic patients (AC) and healthy lean control subjects (C). T2DM underwent 2 weeks of very-low- calorie diet (VLCD - energy content 2500 kJ/day). According to our results we suggest that decreased mRNA expression of IGF-1, IGF-1R, IGFBP-2 and IGFBP-3 in adipose tissue of T2DM subjects may contribute to changes of fat differentiation capacity and the increased IGF-1R mRNA expression in peripheral monocytes in these patients may play a role in the regulation of...